Dulaglutide vs Pramlintide
Research Verdict
Neither compound has a universal evidence advantage. Research distinction: T2DM requiring GLP-1 agonist therapy with CV risk reduction evidence vs. Prandial glucose excursion control, particularly in T1DM where GLP-1 agonists are not indicated - pr.
Quick Answers
Which is better, Dulaglutide or Pramlintide?
Neither compound has a universal evidence advantage. Research distinction: T2DM requiring GLP-1 agonist therapy with CV risk reduction evidence vs. Prandial glucose excursion control, particularly in T1DM where GLP-1 agonists are not indicated - pr.
What is the key difference between Dulaglutide and Pramlintide?
Pramlintide is the only approved amylin analog and works via gastric emptying delay and glucagon suppression at meals; dulaglutide works via GLP-1-mediated insulin secretion and appetite suppression - different mechanisms with different use cases.
Evidence Comparison
Dulaglutide: REWIND CVOT positive, robust Phase 3 program. Pramlintide (Symlin): FDA approved for T1DM and T2DM as prandial adjunct, no CVOT, modest efficacy. Dulaglutide has substantially stronger evidence for major outcomes.
Evidence Context Favoring Dulaglutide
T2DM requiring GLP-1 agonist therapy with CV risk reduction evidence.
Evidence Context Favoring Pramlintide
Prandial glucose excursion control, particularly in T1DM where GLP-1 agonists are not indicated - pramlintide is the only approved amylin analog for T1DM.
Side-by-Side Snapshot
| Evidence grade | Dulaglutide: Level A Pramlintide: Level A |
|---|---|
| Research status | Dulaglutide: FDA Approved Pramlintide: FDA Approved |
| Primary category | Dulaglutide: Weight Loss & Metabolic Pramlintide: Weight Loss & Metabolic |
| Cited studies | Dulaglutide: 3 Pramlintide: 3 |